Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
Intravenous DMT reduced depressive symptoms within a week in Phase IIa trial, with effects lasting up to three months, according to study published in Nature Medicine.
Congressional bill H.R. 5629 threatens to roll back SAMHSA's permanent methadone take-home flexibilities as Pew Charitable Trusts submits testimony defending COVID-era reforms that reduced travel burdens without increasing diversion or deaths.
National coalition urges Congress to maintain SAMHSA, NIH, and addiction program funding in FY2027 appropriations amid proposed 12.5% HHS budget cuts.
House roundtable examines paradox of doubled treatment access, 241% spending increase while depression and suicide reach historic highs. Youth antidepressant prescriptions jump 63%.
World Health Organization updates treatment guidelines adding monthly buprenorphine injections to methadone oral medication recommendations addressing epidemic killing three-quarters million people yearly
Longleaf Lodge launches with 50 residential and 10 detox beds, addressing Alabama's crisis where 19% need substance use treatment but only 5% receive it. Integrated care model tackles co-occurring conditions as wait times stretch weeks to months.
Federal initiative targets individuals experiencing homelessness and substance use disorders through outcomes-based approach, but faith-based inclusion and punitive policy context raise concerns among public health advocates.
Second round of 'transformative grants' prioritizes youth treatment expansion, school prevention programs, and mobile crisis response as state officials emphasize building complete care continuum
Mississippi, Tennessee, Texas, West Virginia, Oklahoma, and Missouri are coordinating clinical trials of ibogaine—a Schedule I psychedelic—for opioid addiction and PTSD despite federal restrictions.